Superior Efficacy and Deep Molecular Remission with Venetoclax Plus Hypomethylating Agent in Elderly Acute Myeloid Leukemia: A Real-World Comparative Cohort Study.

Clin Pharmacol · 2026 · PMC13151982 · PMID 42109308

Europe PMC DOI

hedged sentences

0.1530

closest p · 3.1× alpha

0.1530

boldest claim

The sentences

did not reach statistical significancep=0.153not close (p > 0.1)

Although the comparison of 1-year OS rates among all patients did not reach statistical significance (p=0.153), we observed a numerically higher rate in the VEN-HMA group (55.0%) compared to the HMA-LIIC group (35.0%), and it was comparable to or slightly better than the LIIC group (47.9%), which included potentially younger, more chemotherapy-fit patients.

also in 111,027 other papers

a clear trendno p-value reported

For instance, in the intermediate-risk group, the VEN-HMA group showed a clear trend towards superior survival (1-year OS rate 53.6%), markedly higher than the HMA-LIIC group (21.8%).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.